MMP-17 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human MMP-17 (MT4-MMP; UniProt Q9ULZ9), HEK293-expressed. GPI-anchored membrane-type MMP studied for ECM remodelling, pro-TNF-α processing, and tumour biology research.
Expression system
HEK293
Cat. #
REC-MMP17

In stock

SKU
REC-MMP17
$498.00

Target Overview

MMP-17 (Matrix metalloproteinase-17; UniProt Q9ULZ9) is a GPI-anchored, membrane-type matrix metalloproteinase of the metzincin superfamily, encoded by the MMP17 gene on chromosome 12q24. The full-length human protein spans 603 amino acids and is localised to the cell membrane, where it acts as an extracellular matrix endopeptidase. Unlike the classical secreted MMPs, MMP-17 is tethered to the cell surface via a GPI anchor, placing it within the MT-MMP subfamily alongside MT1-, MT2-, MT3-, and MT5-MMP. This recombinant is expressed in HEK293 mammalian cells, providing human-compatible glycosylation and folding that are relevant for activity and binding studies. The HEK293 system is the preferred host when post-translational modifications may influence substrate recognition or inhibitor interactions — factors that can confound data from bacterial or insect-cell preparations of the same target. Researchers use this recombinant principally in three contexts: (1) enzymatic activity assays against defined peptide or protein substrates, including fibrin and pro-TNF-α-derived sequences; (2) small-molecule or peptide inhibitor IC₅₀ determination, where a well-characterised, active enzyme preparation is required for reproducible kinetic measurements; and (3) antibody validation, where the recombinant serves as a positive-control antigen to confirm specificity and sensitivity of anti-MMP-17 detection reagents. Researchers performing antibody validation with this recombinant can pair it directly with the Triple Point Biologics matched anti-MMP-17 antibody (SKU: RP-MMP17), which has been validated for Western blot applications against human MMP-17.

Background

MMP-17 belongs to the matrix metalloproteinase family, a group of zinc-dependent endopeptidases collectively responsible for regulated turnover of extracellular matrix components and processing of cell-surface signalling molecules. As a GPI-anchored membrane-type MMP (MT4-MMP), MMP-17 occupies a distinct position within the family: it is constitutively expressed on the cell surface without requiring shedding or autocatalytic activation in the conventional sense, and its substrates differ meaningfully from those of the soluble MMPs. The confirmed substrates of MMP-17 include fibrin and, notably, pro-TNF-α, which is cleaved at the Ala⁷⁴–Gln⁷⁵ site. This proteolytic processing of pro-TNF-α places MMP-17 in the same substrate space as ADAM10/17 (TACE), and has motivated published research examining its role in inflammation-related tissue remodelling. MMP-17 does not hydrolyse type I–V collagens, gelatin, fibronectin, laminin, decorin, or α1-antitrypsin under standard conditions, a substrate specificity profile that distinguishes it from the gelatinases (MMP-2/9) and collagenases (MMP-1/8/13). The question of whether MMP-17 can activate pro-MMP-2 (progelatinase A) remains unresolved in the published literature. MMP-17 has been investigated as a research target in multiple disease contexts. Mendelian randomisation approaches have been applied to the broader MMP family — including MMP-17 — to examine causal relationships between circulating MMP levels and conditions such as diabetic retinopathy (Qiu X et al., Medicine (Baltimore), 2026; PMID 41578579). Proteomic profiling studies have identified MMP family members, including MMP-17, as candidates in cerebrospinal fluid biomarker panels for CNS infection. In reproductive biology, exploratory proteomic studies have detected MMP protein-level changes in unexplained infertility cohorts, situating MMP-17 among targets warranting further mechanistic study. In cancer biology, MMP-17 expression has been associated with tumour progression and extracellular matrix remodelling, consistent with its membrane-anchored positioning at the invasive front of epithelial tumours. For researchers studying MMP biology at the cell surface, this HEK293-expressed recombinant provides a defined, mammalian-processed enzyme preparation suited to biochemical characterisation, inhibitor profiling, and generation of validated assay standards.

Applications

  • Endopeptidase activity assay against fluorogenic pro-TNF-α-derived peptide substrates
  • Fibrin degradation assay to characterise MMP-17 fibrinolytic activity
  • Small-molecule inhibitor IC50 determination using continuous fluorescence kinetics
  • Antibody specificity validation by Western blot using recombinant antigen as positive control (pair with TPB RP-MMP17)
  • ELISA standard or capture antigen for quantification of MMP-17 in biological samples
  • Substrate selectivity profiling versus collagen, gelatin, and fibronectin panels to confirm published specificity
  • Surface plasmon resonance or biolayer interferometry binding studies with candidate inhibitors or binding partners

References

  1. Alhalwachi Z et al. An Exploratory Study of Matrix Metalloproteinase Protein Changes in Unexplained Infertility. Life (Basel). 2026. doi:10.3390/life16040676. PMID: 42073484
  2. Ding Y et al. Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Early Central Nervous System Infection. Infect Drug Resist. 2026. doi:10.2147/IDR.S570645. PMID: 41877912
  3. Qiu X et al. Causal relationship between matrix metalloproteinases and diabetic retinopathy: A bidirectional two-sample Mendelian randomization study. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000047363. PMID: 41578579
  4. Chen J et al. Opposing mechanisms by which miRNAs mediate distinct Nrf1 and Nrf2 regulation of epithelial-mesenchymal transition in hepatocellular carcinoma. RNA Biol. 2025. doi:10.1080/15476286.2025.2548628. PMID: 40836845

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What is the expected molecular weight of recombinant MMP-17 on SDS-PAGE and Western blot?

The full-length human MMP-17 protein is 603 amino acids with a predicted unmodified MW of ~67 kDa. The HEK293-expressed recombinant carries human-compatible N-linked glycosylation, so the observed band on reducing SDS-PAGE typically runs at 70–75 kDa. Under non-reducing conditions, you may see a slight upward shift due to disulfide-stabilized conformations. If you are running this alongside RP-MMP17 (our matched rabbit polyclonal), load the recombinant in a separate lane as a size reference — the glycosylated band will migrate distinctly above a deglycosylated or bacterially expressed comparator.

Which processing form of MMP-17 does this recombinant represent — zymogen or active enzyme?

REC-MMP17 is supplied as the active enzyme form, with the prodomain removed. Native MMP-17 is synthesized as an ~75 kDa zymogen and undergoes furin-mediated intracellular processing prior to GPI-anchor tethering at the cell surface. Because the recombinant lacks the GPI anchor (it is expressed as a soluble catalytic-domain-containing fragment), it is free in solution and enzymatically competent without additional activation steps. Researchers running zymogen-activation studies should note this distinction and not expect a pro-form band when using REC-MMP17 as a positive control.

What substrates does MMP-17 cleave and which fluorogenic substrate works best for activity assays?

MMP-17 has a relatively restricted substrate repertoire compared to other MT-MMPs. It cleaves fibronectin and gelatin, and has documented activity against the proteoglycan brevican. For in vitro fluorogenic activity assays, the broad-spectrum MMP substrate Mca-PLGL-Dpa-AR-NH2 (also sold as Peptide Substrate III) is the most widely used and gives reliable signal with REC-MMP17 at 1–10 nM enzyme concentration. Alternatively, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 is suitable if you need to distinguish MT-MMP activity. Use a 96-well black-walled plate and read fluorescence at Ex/Em 320/405 nm.

What buffer conditions should I use for MMP-17 activity assays and is CaCl2 required?

Yes, calcium is essential. MMP-17 is a zinc-dependent metalloproteinase that also requires Ca²⁺ for structural stability. REC-MMP17 is stored in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂ — use this or a closely matched assay buffer. A standard activity assay buffer is 50 mM HEPES pH 7.0, 150 mM NaCl, 10 mM CaCl₂, 0.05% Brij-35. Avoid EDTA or EGTA entirely; even low-µM chelator contamination abolishes activity. ZnCl₂ supplementation (1–5 µM) is optional but can improve signal consistency across freeze-thaw cycles.

What starting concentration of recombinant MMP-17 should I use for an IC50 inhibitor assay?

For inhibitor IC50 determinations, a working enzyme concentration of 1–5 nM REC-MMP17 is appropriate when using Mca-PLGL-Dpa-AR-NH2 at 10 µM substrate. This places you well below substrate KM while maintaining a linear, measurable fluorescence rate over 30–60 minutes. Pre-incubate enzyme with inhibitor for 30 min at 37°C before adding substrate to allow equilibrium binding. If you are benchmarking against a broad MMP inhibitor such as GM6001 or NNGH, expect IC50 values in the low-nanomolar range, which serves as a useful activity verification step before testing novel compounds.

Can I use REC-MMP17 as a positive control for Western blot with the RP-MMP17 rabbit polyclonal antibody?

Yes — this is one of the primary use cases for REC-MMP17. The matched antibody RP-MMP17 (/anti-mmp-17-rabbit-polyclonal-antibody) was validated against this recombinant in-house, so band identity and signal intensity are well characterized. Load 10–50 ng REC-MMP17 per lane on a 10% polyacrylamide gel; the band at ~70–75 kDa will be cleanly detected with RP-MMP17 at a 1:1,000–1:2,000 dilution. Using the recombinant as a positive control is particularly valuable when screening low-expressing cell lysates where an endogenous band may be ambiguous.

How much recombinant MMP-17 should I load as a Western blot positive control for antibody validation experiments?

For antibody validation purposes using RP-MMP17, 20–50 ng per lane is the recommended loading range. At 20 ng, RP-MMP17 at 1:1,000 dilution produces a strong, clean band at ~70–75 kDa with minimal background under standard ECL detection. Titrating down to 5 ng is feasible with high-sensitivity substrates if you want to demonstrate antibody sensitivity. Include a no-primary-antibody lane as a negative control. Because REC-MMP17 and RP-MMP17 originate from the same production lot validation workflow, this pairing meets the antibody validation criteria outlined in the 2016 Nature Methods guidelines.

How should I handle, dilute, and store recombinant MMP-17 to maintain activity over time?

REC-MMP17 is shipped on dry ice and should be stored at −20°C immediately upon receipt. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂) is formulated to protect enzymatic activity through a single freeze-thaw cycle; aliquot into single-use volumes before freezing to avoid repeated thawing. For working dilutions, use assay buffer (not water) to prevent activity loss from dilution-shock. Once thawed, keep on ice and use within 4 hours. Do not vortex; mix gently by pipetting. Shelf life at −20°C is 12 months from the date of manufacture when stored correctly.

Validation imagery coming soon

Western blot validation figures for REC-MMP17 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →